Barclays Upgrades Quest Diagnostics to Overweight, Raises Price Target to $210

Barclays signals renewed faith in Quest Diagnostics' testing business

NEW YORK — Barclays upgrades Quest Diagnostics to "Overweight," raising its price target to $210, a move that reflects growing analyst confidence in the company’s position in clinical laboratory testing. The upgrade arrives as payers and providers increasingly rely on large national laboratories to deliver routine and specialty testing with scale efficiencies. Barclays’ action is read by market watchers as an endorsement of Quest’s ability to sustain volumes and leverage fixed-cost advantages across its national network.

Analysts say the upgrade underscores structural strengths in Quest’s core diagnostics franchise rather than short-term market swings. Quest operates one of the largest networks of reference labs in the U.S., which supports customer consolidation from hospitals, physicians and outpatient centers seeking standardized testing and faster turnaround. The firm’s scale also positions it to negotiate with payers and to invest in automation and data services that can drive margin improvement as testing demand stabilizes post-pandemic.

The move also highlights industry dynamics around consolidation, pricing pressure and innovation in diagnostics services. Quest faces direct competition from other national labs and emerging diagnostics firms, but an upgrade by a major bank suggests expectations that Quest’s strategic initiatives — such as partnerships, digital ordering and lab automation — can translate into steadier revenue and improved profitability. Investors and clients alike watch how Quest balances near-term reimbursement pressure with long-term opportunities in personalized medicine and diagnostic data analytics.

Analyst calls across sectors bring a varied outlook

Other broker activity this week reflects a wide-ranging market reassessment. Goldman Sachs upgrades Futu Holdings to "Buy" from "Neutral," assigning a 12-month price target of $213.39 and citing favorable capital markets conditions and client growth; Bank of America reiterates a "Buy" on Nvidia, citing its role in AI computing and networking.

The broader slate of changes includes HSBC downgrading Chevron to "Neutral," Citi upgrading Teck Resources to "Buy" on a merger with Anglo American, and Barclays’ move on Quest sitting alongside upgrades and reinstatements in consumer and energy names. Goldman also adds DoorDash, Golar LNG and ServiceNow to its conviction buy list, underscoring the cross-sector strategic re-evaluations shaping analyst recommendations.